Heme Oxygenase-1 and breast cancer resistance protein protect against heme-induced toxicity

Publication date

2013

Authors

Wagener, Frank A D T G
Dankers, Anita C A
van Summeren, Frank
Scharstuhl, Alwin
van den Heuvel, Jeroen J M W
Koenderink, Jan B
Pennings, Sebastiaan W C
Russel, Frans G M
Masereeuw, RosalindeORCID 0000-0002-1560-1074ISNI 0000000369326917

Editors

Advisors

Supervisors

Document Type

Article

License

Abstract

Heme is the functional group of diverse hemoproteins and crucial for many cellular processes. However, heme is increasingly recognized as a culprit for a wide variety of pathologies, including sepsis, malaria, and kidney failure. Excess of free heme can be detrimental to tissues by mediating oxidative and inflammatory injury. Protective mechanisms against free heme are therefore pivotal for cellular survival. We postulated that overexpression of Heme Oxygenase-1 (HO-1) and Breast Cancer Resistance Protein (BCRP) would protect against heme-induced cytotoxicity. HO-1 is a heme-degrading enzyme generating carbon monoxide, iron, and biliverdin/bilirubin, while BCRP is a heme efflux transporter. Human embryonic kidney cells were transduced using a baculovirus system as a novel strategy to efficiently overexpress HO-1 and BCRP. Exposing cells to heme resulted in a dose-dependent increase in reactive oxygen species formation, DNA damage and cell death. Heme-induced cell death was significantly attenuated when cells overexpressed HO-1, BCRP, or both. The protective effects of HO-1 overexpression were most pronounced, while co-treatment with the HO-activity inhibitor tin mesoporphyrin reversed these protective effects. Also cells treated with the anti-oxidants N-acetylcysteine or HO-effector molecule bilirubin showed protection against heme insults, which may explain the increased protection by HO-1 compared to BCRP. In conclusion, both HO-1 and BCRP protect against heme-induced toxicity and may thus form novel therapeutic targets for heme-mediated pathologies.

Keywords

ATP-Binding Cassette Transporters, Benzimidazoles, Blotting, Western, DNA Damage, HEK293 Cells, Heme, Heme Oxygenase-1, Humans, Neoplasm Proteins, Oxidants, Reactive Oxygen Species, SDG 3 - Good Health and Well-being

Citation

Wagener, F A D T G, Dankers, A C A, van Summeren, F, Scharstuhl, A, van den Heuvel, J J M W, Koenderink, J B, Pennings, S W C, Russel, F G M & Masereeuw, R 2013, 'Heme Oxygenase-1 and breast cancer resistance protein protect against heme-induced toxicity', Current Pharmaceutical Design, vol. 19, no. 15, pp. 2698-707. https://doi.org/10.2174/1381612811319150004